WeChat Quit Coach Pilot Study
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The study team will develop and assess the feasibility and acceptability of a WeChat-based peer-group mobile messaging smoking cessation intervention targeting Chinese immigrant smokers in New York City (NYC). For Aim 1, the study team will develop a message library for the WeChat Quit Coach smoking cessation program and conduct in-depth interviews with 20 Chinese immigrant smokers in person to assess content relevance. For Aim 2, a two-arm, open-labeled, pilot randomized controlled trial (RCT) will be conducted to test the feasibility and acceptability of the WeChat Quit Coach intervention among 60 Chinese immigrant smokers. Participants will be randomized to intervention (n=40) or control group (n=20). Participants in the intervention group will receive a 6-week WeChat Quit Coach intervention through WeChat private group. Participants in the control group will receive a leaflet with information about existing smoking cessation programs that focus on Chinese American smokers. All the 60 participants will be offered a 4-week supple of nicotine replacement therapy (NRT) patches and/or lozenges. Participants will complete a baseline in-person survey at enrollment, a 6-week follow-up phone survey immediately after the intervention, and a 6-month follow-up phone survey. Biochemical test (exhaled carbon monoxide test) will be conducted to confirm abstinence among those who report no smoking in past 7-day at 6-week and 6-month follow-up surveys. Post-test in-depth interviews will be conducted with at least 20 participants in person from the intervention group at 6-week follow-up to obtain more information about the usability and perceptions about the WeChat Quit Coach program. For Aim 3, the investigators will conduct an open-labeled, 3-arm pilot RCT to test the preliminary effectiveness of the WeChat Quit Coach intervention with 90 Chinese immigrant smokers. Participants will be randomized to one of the three groups, including a 6-week intervention group A (IA; n = 30), a 12-week intervention group B (IB; n = 30), and a control group (n = 30). Participants in the intervention groups will either receive a 6-week (IA) or 12-week (IB) WeChat Quit Coach intervention through WeChat private groups. Participants in the control group will receive a leaflet with information of existing smoking cessation programs targeting Chinese American smokers. All 90 participants will be offered a 4-week free supply of NRT patches and/or lozenges. Participants will complete a baseline phone survey at enrollment, 12-week and 6-month follow-up phone surveys. A remote biochemical validation (saliva cotinine test) will be conducted at 12-week and 6-month follow-up to confirm smoking abstinence among those who self-report no smoking in the past 7 days. Post-test in-depth phone interviews will be conducted with up to 30 intervention participants to obtain more information about their perceptions and experience with the WeChat Quit Coach program.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Aim 2:
- Age 18-80 years
- Chinese immigrant
- Have smoked at least 100 cigarettes in a lifetime
- Smoke ≥3 days per week
- Be somewhat interested in quitting smoking
- Has a Smartphone
- Current WeChat user who uses WeChat on ≥3 days per week
- Live in NYC
- Can read and speak Chinese
- Be able to provide consent
Aim 3:
- Age 18 years or above
- Chinese immigrant
- Have smoked at least 100 cigarettes in a lifetime
- Smoke ≥1 days per week
- Current WeChat user who uses WeChat on ≥3 days per week
- Can read and speak Chinese
Exclusion criteria
Aim 2:
- Current participation in other smoking cessation treatment program(s)
- Be pregnant or breastfeeding
Aim 3:
- Current participation in other smoking cessation treatment program(s)
- Be pregnant or breastfeeding
- Having a household member who has enrolled in this study
Trial design
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Nan Jiang, PhD; Jennifer (Jingrui) Yang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal